English

SLS Invest to strengthen its Board of Directors

Report this content

Stockholm, April 12, 2011. SLS Invest AB – one of Scandinavia’s leading investors focusing on Life Sciences – has elected Martin Nicklasson as new Member of the Board. Martin Nicklasson has vast experience from leading positions in several pharmaceutical companies. He was most recently CEO and President for Swedish Orphan Biovitrum (SOBI), a Swedish based pharmaceutical company.

Lars Ingelmark, Chairman of the Board, SLS Invest:
“SLS Invest’s portfolio has reached a point where a number of the companies have products on the market, or are in the position where they have initiated – or prepare to initiate – discussions with potential partners. Martin Nicklasson has many years of business development experience from leading positions in global pharmaceutical companies, which will be of great importance for the continued development of SLS Invest’s portfolio companies”.

Martin Nicklasson is a former member of the executive management at AstraZeneca Plc. He has held a number of leadership positions within Astra and AstraZeneca, including CEO of Astra Pain Control AB, CEO of Astra Hässle AB, Head of Gastrointestinal Franchise, Executive Vice President of Global Drug Development, Executive Vice President of Global Marketing and CEO of AstraZeneca AB. Martin has also held leading positions within research at Kabi Pharmacia. He was most recently CEO and President for Swedish Orphan Biovitrum (SOBI).

For further information, please contact;

Lars Ingelmark, Chairman of the Board, SLS Invest
Tel: +46 708 741035, e-mail: lars.ingelmark@apfond6.se

TO THE EDITORS
About SLS Invest
Being in business since 2002 and managing assets exceeding MEUR 100, SLS Invest is one of the leading Scandinavian evergreen funds focusing on life science. With offices in Stockholm and Copenhagen, six investment professionals with vast life science and operational experience and a mature portfolio addressing unmet medical needs, SLS Invest offers the opportunity to invest in novel treatments and devices with high medical – and thereby commercial – potential. www.slsinvest.com www.slsinvest.com

Documents & Links